摘要
目的研究近10年国际上贝利尤单抗治疗系统性红斑狼疮的现状及热点。方法检索Web of Science数据库中发表于2011-2020年贝利尤单抗治疗系统性红斑狼疮的相关文献,采用CiteSpace 5.7.R2软件对文献进行可视化分析,从发文量、作者和被引作者、机构、国家、期刊、研究领域分析贝利尤单抗治疗系统性红斑狼疮的研究现状、通过文献共被引及关键词的知识图谱分析该领域的知识基础、研究热点及研究前沿变化。结果共纳入文献457篇,发文量呈逐年递增趋势,发文量靠前的国家有美国、英国、意大利、德国、瑞典,发文量最多的机构为英国葛兰素史克,作者是美国南加州大学凯克医学院的Stohl W,被引频次最多的作者是美国纽约扎克医学院的学者Furie R,期刊是Arthritis Rheum-US。该领域主要研究热点是贝利尤单抗治疗系统性红斑狼疮有效性研究、长期疗效及安全性研究、皮下剂型研究、与利妥昔单抗联用相关研究、特殊人群疗效与安全性研究等。研究前沿趋势变化为由贝利尤单抗治疗系统性红斑狼疮有效性和安全性研究转向特殊人群(如儿童患者、狼疮肾炎患者、重度活动度患者、神经狼疮患者等)临床应用研究。结论近10年来贝利尤单抗治疗系统性红斑狼疮的研究越来越受到临床医师和学者的重视,研究主要集中在贝利尤单抗治疗系统性红斑狼疮的有效性、长期疗效和安全性等方面,未来应更多地关注在特殊人群中的疗效和安全性研究。
Objective To analyze the research status,and hot spots of belimumab for systemic lupus erythematosus internationally over the past decade.Methods Articles and reviews related to belimumab for systemic lupus erythematosus published from 2011 to 2020 were retrieved from Web of Science.CiteSpace 5.7.R2 was used for visualized analysis of the literatures.The information of belimumab for systemic lupus erythematosus was collected concerning the number of articles published,authors,institutions,countries/regions,journals and categories.The knowledge,research hotspots and frontier changes in this field were analyzed based on the knowledge map of literature co-citations and keywords.Results Totally 457 publications were included,and the annual output kept increasing,with the top countries covering the United States,the United Kingdom,Italy,Germany and Sweden.The GlaxoSmithKline in the UK had the most publications.The author with highest number of studies was Stohl W from the University of Southern California Keck School of Medicine,and the author with the highest citation was Furie R,a scholar from the Zucker School of Medicine in New York,United States.Arthritis Rheum-US was the most-cited journal.The main research of belimumab for systemic lupus erythematosus focused on the effectiveness,long-term efficacy and safety,subcutaneous dosage forms,combination with rituximab,efficacy and safety among the special populations,etc.The study frontiers shifted from the efficacy and safety of belimumab for systemic lupus erythematosus to clinical applications among child patients,patients with lupus nephritis,severe activity,neurolupus,etc.).Conclusion Over the past decade,the studies of belimumab for systemic lupus erythematosus have attracted much attention from clinicians and scholars.The studies mainly focus on the efficacy,long-term efficacy and safety of belimumab for systemic lupus erythematosus.More attention will be paid to the efficacy and safety among special populations.
作者
赵院霞
楚尧娟
薛莹
卢晓静
史香芬
王松
杜书章
ZHAO Yuan-xia;CHU Yao-juan;XUE Ying;LU Xiao-jing;SHI Xiang-fen;WANG Song;DU Shu-zhang(Department of Pharmacy,The First Affiliated Hospital of Zhengzhou University,Zhengzhou 450052)
出处
《中南药学》
CAS
2022年第1期171-178,共8页
Central South Pharmacy
基金
国家重点研发计划(编号:2017YFC0909900)。
